- $606.55m
- $261.60m
- $76.01m
- 48
- 20
- 48
- 33
Annual income statement for Zymeworks, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 29.5 | 39 | 26.7 | 412 | 76 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 181 | 226 | 242 | 282 | 214 |
| Operating Profit | -151 | -187 | -216 | 131 | -138 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -146 | -180 | -212 | 135 | -119 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -145 | -181 | -212 | 124 | -119 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -145 | -181 | -212 | 124 | -119 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -145 | -181 | -212 | 124 | -119 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.8 | -3.61 | -4.15 | 1.9 | -1.72 |